Shoaib Ahmad, MD
Pulmonary Disease · Oklahoma City, OKNPI 1255651477
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.1%), education and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Intuitive Surgical at 44.9% of the total. Reporting peaked in 2023 at $4,857 and has fallen 68.0% since, to $1,553 in 2025.
Across 201 payments — averaging $38.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AstraZeneca$753
- Boehringer Ingelheim$587
- GSK$521
- Insmed, Inc.$502
- Paragonix Technologies, Inc.$266
- plus $2K from 20 others
What the payments were for
- Travel & lodging$4746%
- Food & beverage$4,20554%
- Education$3,09940%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $3,490 |
| AstraZeneca(2 entities) | 34 | $753 |
| Boehringer Ingelheim | 24 | $587 |
| GSK | 32 | $521 |
| Insmed, Inc. | 23 | $502 |
| Paragonix Technologies, Inc. | 2 | $266 |
| Actelion Pharmaceuticals US, Inc. | 7 | $245 |
| Gilead | 8 | $134 |
| Pulmonx Corporation | 5 | $116 |
| United Therapeutics Corporation | 5 | $116 |
| Regeneron Healthcare Solutions, Inc. | 5 | $110 |
| Amgen | 5 | $106 |
| Mylan Specialty L.p. | 5 | $102 |
| Sanofi | 5 | $99 |
| Novartis | 6 | $98 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Baxter Healthcare | 3 | $86 |
| Genentech USA, Inc. | 4 | $75 |
| Sunovion Pharmaceuticals Inc. | 8 | $74 |
| Pfizer | 2 | $49 |
| Johnson & Johnson(2 entities) | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| AbbVie | 1 | $32 |
| Lilly USA, LLC | 1 | $21 |
| Verona Pharma, Inc. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,418
- LUNGguard$266
- BaroGuard$266
How this compares
$7,778 in reported general payments places this provider in the 75th percentile of 133 pulmonary disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 396 | $287,282 |
| Fasenra PenBenralizumab | 13 | $74,442 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $74,414 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $35,657 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $29,633 |
| Spiriva RespimatTiotropium Bromide | 24 | $13,540 |
| Incruse ElliptaUmeclidinium Bromide | 37 | $12,944 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 73 | $9,928 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $8,429 |
| Wixela InhubFluticasone Propion/Salmeterol | 47 | $6,302 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 221 | $4,222 |
| Ventolin HfaAlbuterol Sulfate | 28 | $2,283 |
| Varenicline Tartrate | 12 | $1,437 |
| Fluticasone Propionate | 121 | $1,323 |
| Ipratropium Bromide | 25 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $521 | $365,516572 claims |
| AstraZenecaBreztri Aerosphere | $753 | $74,414100 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $587 | $21,96940 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 133 pulmonary disease providers in Oklahoma.
Other pulmonary disease in Oklahoma City
- John KingreyOklahoma City$332K
- Fawad ChaudryOklahoma City$80K
- Maroun TawkOklahoma City$62K
- Nathaniel MoultonOklahoma City$28K
- Syed NaqviOklahoma City$15K
- Tarek DernaikaOklahoma City$12K
- Shoab NazirOklahoma City$11K
- Mark GodishOklahoma City$11K
- Mazen ZouwayhedOklahoma City$10K
- Azhar KhanOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.